FDA perspective on anti-TNF treatments.
Schwieterman
W D
WD
Immunology and Infectious Disease Branch, Division of Clinical Trial Design and Analysis, Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852, USA.
D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D006801:Humans; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D014481:United States; D014486:United States Food and Drug Administration
D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha